The World Health Organization (WHO) has issued an urgent alert about falsified OZEMPIC (semaglutide) detected in Brazil, the UK, and the USA. These counterfeit products pose significant health risks, including ineffective treatment and potential contamination. Identified batches include LP6F832, NAR0074 with serial number 430834149057, and falsified versions of genuine batch MP5E511. The public is advised to avoid these batches, and healthcare professionals are urged to report any adverse effects to national authorities. WHO recommends verifying lot and serial numbers, examining the quality of the pen, and checking for errors on labels to identify falsified products.
Search this website
All topics
- Access to medicines (43)
- Alerts and recalls (7)
- Audits & Inspections (2)
- BPF (1)
- BPSD (2)
- ENABEL (6)
- Falsified and sub-standard medicines (10)
- GSDP (2)
- International (10)
- ITM (1)
- Latin America (1)
- Literature updates (32)
- MQAS (11)
- National regulatory authority (3)
- News (33)
- PAHO (2)
- Podcast (2)
- QA standards (13)
- QCP (11)
- Quality assurance (33)
- Quamed News (253)
- Recruitment (9)
- Research (7)
- Technical visits (2)
- Training (8)
- USAID (5)
- Webinaire (1)
- Webinar (23)
- WHO (28)
